tesofensine Report issue

Small molecule Experimental
AACT ChEMBL PubChem

Active Ingredient History

NOW
  • Now
Tesofensine (NS2330) is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.   Wikipedia

Chemistry

  • SMILES: CCOC[C@H]1[C@H]2CC[C@@H](C[C@@H]1c3ccc(Cl)c(Cl)c3)N2C
  • InChIKey: VCVWXKKWDOJNIT-ZOMKSWQUSA-N
  • Mol. Mass: 328.28
  • ALogP: 4.6
  • ChEMBL Molecules:
    tesofensine  
    None  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

ns2330 | tesofensine

Organizations (7)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Alzheimer Disease (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Diagnosis (Phase 2)

Healthy Volunteers (Phase 1)

Obesity (Phase 2)

Parkinson Disease (Phase 2)

Prader-Willi Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 14
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue